Dr Lorenz Isert,
Projectlead R&D, AMW GmbH
Working with Dr Adrian Kromer was extremely valuable for our project. His in-depth knowledge of design of experiments won us over. It quickly becomes clear that he has already solved many complex problems and developed practical approaches based on his experience.
Thanks to his advice, we were able to drastically reduce the amount of formulation work – to about a third of the original scope. It is particularly noteworthy that Dr Adrian Kromer not only developed a statistically optimal approach, but also presented us with several options that were perfectly tailored to our resources and the requirements of our development department. This enabled us to achieve the best possible result. His influence on our work was also evident in the fact that test and project goals were specified, timelines were adjusted and expectation management was significantly improved. This enabled our team to work much more efficiently.
We were completely satisfied – from his high availability and short response times to his professionalism and consistent adherence to deadlines. The direct and uncomplicated exchange significantly accelerated the process. Through regular coordination, the test plans could be adjusted step by step and further improved in terms of quality.
We would recommend Dr Adrian Kromer at any time and would also hire him again. His advice not only improved our project work, but also gave us a clearer internal vision for the overall project.
Translated from the original German version.
Dr Benjamin Winkeljann, CEO, RNhale GmbH
As an emerging biotech company with a proprietary platform for inhalable RNA therapeutics, we at RNhale face the challenge of developing LNP formulations that differ fundamentally from conventional approaches: optimised for further processing into dry powder and application in the lungs. In this context, the collaboration with Dr Adrian Kromer was a decisive step for our asthma and COPD programme.
His in-depth knowledge in the field of design of experiments and its integration into our QbD approach enabled us to systematically identify critical parameters and build robust models for formulation development. Dr Kromer presented us with several strategic options tailored to our resources and regulatory requirements. The collaboration was characterised by a high level of professionalism, clear communication and an ability to clearly convey complex statistical concepts in the specific field of drug development.
We highly recommend Dr Adrian Kromer and would work with him again at any time in the future.
Translated from the original German version.